Optimal baseline prostate-specific antigen level to distinguish risk of prostate cancer in healthy men between 40 and 69 years of age
- PMID: 22219612
- PMCID: PMC3247773
- DOI: 10.3346/jkms.2012.27.1.40
Optimal baseline prostate-specific antigen level to distinguish risk of prostate cancer in healthy men between 40 and 69 years of age
Abstract
The present study evaluated optimal baseline prostate-specific antigen (PSA) level at different ages in order to determine the risk of developing prostate cancer (CaP). We analyzed 6,651 Korean men, aged 40-69 yr. The serum PSA levels for these men were measured at one institute from 2000 to 2004 and were determined to be between 0-4 ng/mL. Patients were divided into 4 groups of 25th-percentile intervals, based on initial PSA level. Of these, the group with an increased risk was selected, and the optimal value was determined by the maximal area under a receiver-operating characteristic curve within the selected group. The risk of CaP diagnosis was evaluated by Cox regression. The mean follow-up period was 8.3 yr. CaP was detected in 27 of the 6,651 subjects. CaP detection rate was increased according to age. The optimal PSA value to distinguish the risk of CaP was 2.0 ng/mL for 50- to 69-yr-olds. Patients with a baseline PSA level greater than the optimal value had a 27.78 fold increase in the prostate cancer risk. Baseline PSA values are useful for determining the risk of developing CaP in Korean men for 50- and 69-yr-old. We suggest that PSA testing intervals be modified based on their baseline PSA levels.
Keywords: Asian Continental Ancestry Group; Prostate Neoplasm; Prostate-Specific Antigen; Screening.
Figures


Similar articles
-
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.Urology. 2006 Feb;67(2):316-20. doi: 10.1016/j.urology.2005.08.040. Epub 2006 Jan 25. Urology. 2006. PMID: 16442597
-
The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort.Eur Urol Oncol. 2024 Dec;7(6):1535-1542. doi: 10.1016/j.euo.2024.06.014. Epub 2024 Jul 10. Eur Urol Oncol. 2024. PMID: 38991891
-
PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study.Urology. 2002 Sep;60(3):464-8. doi: 10.1016/s0090-4295(02)01760-0. Urology. 2002. PMID: 12350485 Clinical Trial.
-
Baseline prostate-specific antigen testing at a young age.Eur Urol. 2012 Jan;61(1):1-7. doi: 10.1016/j.eururo.2011.07.067. Epub 2011 Aug 10. Eur Urol. 2012. PMID: 21862205 Review.
-
Significance of serum free prostate specific antigen in the screening of prostate cancer.J Urol. 1996 Dec;156(6):1964-8. J Urol. 1996. PMID: 8911366 Review.
Cited by
-
Unveiling the Link between Prostatitis and Periodontitis.Contemp Clin Dent. 2018 Oct-Dec;9(4):524-529. doi: 10.4103/ccd.ccd_746_18. Contemp Clin Dent. 2018. PMID: 31772457 Free PMC article.
-
Solitary fibrous tumors of the prostate: A case report.Oncol Lett. 2015 Sep;10(3):1617-1619. doi: 10.3892/ol.2015.3379. Epub 2015 Jun 16. Oncol Lett. 2015. PMID: 26622720 Free PMC article.
-
Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL.World J Urol. 2014 Apr;32(2):481-7. doi: 10.1007/s00345-013-1089-0. Epub 2013 Apr 26. World J Urol. 2014. PMID: 23619479
-
Comparison of pathological and biochemical outcomes after radical prostatectomy in Korean patients with serum PSA ranges.J Korean Med Sci. 2015 Mar;30(3):317-22. doi: 10.3346/jkms.2015.30.3.317. Epub 2015 Feb 16. J Korean Med Sci. 2015. PMID: 25729256 Free PMC article.
-
Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis.Investig Clin Urol. 2022 May;63(3):251-261. doi: 10.4111/icu.20210429. Investig Clin Urol. 2022. PMID: 35534215 Free PMC article.
References
-
- Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70–98. - PubMed
-
- Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182:2232–2241. - PubMed
-
- Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol. 2005;174:872–876. - PubMed
-
- Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006;67:316–320. - PubMed
-
- Choi YD, Kang DR, Nam CM, Kim YS, Cho SY, Kim SJ, Cho IR, Cho JS, Hong SJ, Ham WS. Age-specific prostate-specific antigen reference ranges in Korean men. Urology. 2007;70:1113–1116. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous